寻找平衡:静脉血栓塞栓症在克罗恩病中血液缩期间的预防
Kain Kim1, Danielle Llanos1, Christopher Ramos2
1Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Case reports in gastroenterology
|August 15, 2024
概括
患有炎症性肠病 (IBD) 的住院患者具有高风险的静脉血栓塞栓症 (VTE). 这一案例突出了下静脉膜过器 (IVCF) 在治疗反复发生的静脉膜炎时的使用,当抗凝药是禁忌的.
科学领域:
- 胃肠病学 胃肠病学
- 血管外科 血管外科
- 血液学 血液学 血液学
背景情况:
- 患有炎症性肠病 (IBD) 的患者面临静脉血栓塞栓症 (VTE) 的风险增加.
- 在住院的IBD患者中,对VTE的药理学预防尚未得到充分利用,特别是那些患有血的患者.
- 临床指南在VTE预防中为可检索下静脉膜过器 (rIVCF) 提供了不一致的建议.
研究的目的:
- 在患有胃肠道出血而入院的患者中,为复发性静脉瘤提供一个使用rIVCF的案例.
- 为了强调在活跃的IBD患者中进行VTE预防的重要性,即使有血.
- 讨论IVCFs在某些具有抗凝固药物禁忌的患者中的作用.
主要方法:
- 病例报告详细介绍了IBD患者胃肠道出血的复发性VTE的治疗方法.
- 对临床指导方针和关于VTE预防和IVCF安置的实践变化进行审查.
主要成果:
- 该案例说明了在患有IBD和出血的患者中使用rIVCF成功管理复发性VTE.
- 突出了这种复杂的患者群体中VTE预防和管理的挑战.
结论:
- 在患有活跃IBD的患者中,VTE预防的较低门是合理的,无论他们是否呈现出血症等症状.
- 下静脉膜过器 (IVCFs) 可能是必要的,对于复发性VTE和抗凝药的禁忌患者的一个子集.
- 密切跟踪和监测IVCF相关并发症至关重要.
相关概念视频
01:28Esophageal Varices-II: Clinical Features and Management
57
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
57
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
654
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
654
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
103
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
103
01:29Drugs for Treatment of Ulcerative Colitis in IBD
131
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
131
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
120
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
120